NFA
CLSD

Nationwide Fund Advisors’s Clearside Biomedical CLSD Stock Holding History

Nationwide Fund Advisors’s Portfolio CLSD Stock Details CLSD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-780
Closed -$102K – 416
2017
Q3 		$102K Hold
780
– – ﹤0.01% 2890
2017
Q2 		$107K Buy
780
+423
+118% +$50.8K ﹤0.01% 2868
2017
Q1 		$43K Hold
357
– – ﹤0.01% 3006
2016
Q4 		$48K Buy
+357
New +$89.6K ﹤0.01% 3006

Other funds holding CLSD

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Nationwide Fund Advisors's CLSD Position: Q4 2017 in Review

Nationwide Fund Advisors sold out of Clearside Biomedical (CLSD) in Q4 2017, closing a stake of 780 shares — an estimated $102K sold.

Nationwide Fund Advisors first reported a position in CLSD in Q4 2016 and held it in 4 quarters. The position peaked at $107K in Q2 2017. 54 funds tracked by Wall St. Rank hold CLSD as of Q4 2017.

  • Nationwide Fund Advisors reported no remaining Clearside Biomedical position as of Q4 2017 after selling out during the quarter.
  • Nationwide Fund Advisors sold 780 Clearside Biomedical shares in Q4 2017, an estimated $102K.
  • Nationwide Fund Advisors first reported a position in Clearside Biomedical in Q4 2016 and held it in 4 quarters.
  • Nationwide Fund Advisors's Clearside Biomedical position peaked at $107K in Q2 2017.
  • 54 funds tracked by Wall St. Rank held Clearside Biomedical as of Q4 2017.

Based on Nationwide Fund Advisors's 13F filing for Q4 2017, filed 1 Feb 2018.